H.C. Wainwright downgraded iTeos Therapeutics (ITOS) to Neutral from Buy without a price target after GSK decided to terminate the development of belrestotug, marking the end of clinical development of all Fc-competent anti-TIGIT antibodies. The two partners are discontinuing all belrestotug-related studies, the analyst tells investors in a research note. As a result, H.C. Wainwright moved to the sidelines on shares of iTeos Therapeutics.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics downgraded to Market Perform from Outperform at Leerink
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth
- iTeos Therapeutics downgraded to Neutral at JPMorgan after TIGIT program ended
- iTeos Therapeutics downgraded to Neutral from Overweight at JPMorgan
- iTeos Therapeutics Ends Collaboration with GSK
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue